Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.38 |
| ▸ | HTR2C | P28335 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMARCA4 | P51532 | 4/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | PBRM1 | Q86U86 | 3/20 | 0.35 |
| ▸ | PER2 | O15055 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18202172 | 0.80 | HTR2A (0.55) | HTR2AHTR2CKDM4EMAPTSMARCA4 | |
| SCHEMBL19960987 | 0.78 | HTR2A (0.42) | HTR2AHTR2CKDM4EMAPTRECQL | |
| SCHEMBL19960981 | 0.77 | HTR2A (0.41) | HTR2AHTR2CKDM4EMAPTPER2 | |
| SCHEMBL19930320 | 0.77 | MTNR1A (0.41) | HTR2AHTR2CKDM4EMAPTSMARCA4 | |
| SCHEMBL19960975 | 0.76 | PABPC1 (0.45) | HTR2AHTR2CKDM4EMAPTSMARCA4 | |
| SCHEMBL19960977 | 0.72 | HTR2A (0.35) | HTR2AHTR2CKDM4EMAPTPER2 | |
| SCHEMBL19960980 | 0.72 | HTR2A (0.36) | HTR2AHTR2CKDM4EMAPTRECQL | |
| SCHEMBL19960978 | 0.72 | HTR2A (0.36) | HTR2AHTR2CKDM4EMAPT | |
| SCHEMBL19960986 | 0.71 | PER2 (0.36) | HTR2AHTR2CRECQLPER2 | |
| SCHEMBL9382916 | 0.70 | SIGMAR1 (0.47) | HTR2AHTR2CKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | EGFR, ERBB2, ERBB4 | HTR2A 3470/4885HTR2C 2254/4885KDM4E 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.